Drug Approval | November 23, 2023
The product will be manufactured at Lupin’s Nagpur facility in India
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
PhytoSquene now available for clinical and commercial use
This product will be manufactured at Lupin’s Pithampur facility in India
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Subscribe To Our Newsletter & Stay Updated
